Treatment of Bipolar Depression: Evolving Recommendations

Psychiatric Clinics of North America

Volumn 39, Issue 1, 2016, Pages 11-33

  Post, Robert M ^a  

^a Bipolar Collaborative Network   (United States)

Author keywords

Anticonvulsants; Anxiety; Atypical antipsychotics; Lithium; Neurotrophic factors; Psychoeducation; Rapid cycling; Substance abuse

Indexed keywords

ACETYLCYSTEINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARBAMAZEPINE; CARIPRAZINE; FLUOXETINE PLUS OLANZAPINE; FOLIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; LAMOTRIGINE; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM CARBONATE; LURASIDONE; MINOCYCLINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NIMODIPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SCOPOLAMINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE; LITHIUM;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; CACNA1C GENE; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DRUG ABSORPTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EXERCISE; FAMILY FOCUSED TREATMENT; GENE; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; LOW DRUG DOSE; MAGNETIC FIELD; MAJOR DEPRESSION; MANIA; METABOLIC SYNDROME X; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; OFF LABEL DRUG USE; ONSET AGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REFRACTORY DEPRESSION; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SMOKING; SUBSTANCE ABUSE; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION; WEIGHT GAIN; ANXIETY DISORDERS; BIPOLAR DISORDER; COMPLICATION;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; HUMANS; LITHIUM;

EID: 84957799552     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2015.09.001     Document Type: Review

References (63)

1. Kupka R.W., Altshuler L.L., Nolen W.A., et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007, 9(5):531-535.
2. Sidor M.M., Macqueen G.M. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011, 72(2):156-167.
3. Post R.M., Altshuler L.L., Frye M.A., et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010, 71(9):1176-1186. [quiz: 1252-73].
4. Post R.M., Leverich G.S., Altshuler L.L., et al. Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry 2012, 73(7):924-930.
5. McElroy S.L., Weisler R.H., Chang W., et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71(2):163-174.
6. Baldessarini R.J., Leahy L., Arcona S., et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007, 58(1):85-91.
7. Davis J.M., Wang Z., Janicak P.G. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 1993, 29(2):175-181.
8. Geddes J.R., Carney S.M., Davies C., et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003, 361(9358):653-661.
9. Amsterdam J.D., Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010, 167(7):792-800.
10. Post R.M., Altshuler L.L., Leverich G.S., et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006, 189:124-131.
11. Vieta E., Manuel Goikolea J., Martinez-Aran A., et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006, 67(3):473-477.
12. Martin A., Young C., Leckman J.F., et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004, 158(8):773-780.
13. Altshuler L.L., Suppes T., Black D.O., et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006, 163(2):313-315.
14. Frye M.A., Helleman G., McElroy S.L., et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009, 166(2):164-172.
15. Valenti M., Pacchiarotti I., Rosa A.R., et al. Bipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients. Bipolar Disord 2011, 13(2):145-154.
16. Goldberg J.F., Perlis R.H., Ghaemi S.N., et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 2007, 164(9):1348-1355.
17. Gijsman H.J., Geddes J.R., Rendell J.M., et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004, 161(9):1537-1547.
18. Vieta E., Martinez-Aran A., Goikolea J.M., et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002, 63(6):508-512.
19. Sachs G.S., Lafer B., Stoll A.L., et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994, 55(9):391-393.
20. Goldberg J.F., Whiteside J.E. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 2002, 63(9):791-795.
21. Pacchiarotti I., Bond D.J., Baldessarini R.J., et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013, 170(11):1249-1262.
22. Altshuler L., Kiriakos L., Calcagno J., et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001, 62(8):612-616.
23. Altshuler L., Suppes T., Black D., et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003, 160(7):1252-1262.
24. Joffe R.T., MacQueen G.M., Marriott M., et al. One-year outcome with antidepressant-treatment of bipolar depression. Acta Psychiatr Scand 2005, 112(2):105-109.
25. Ghaemi S.N., Ostacher M.M., El-Mallakh R.S., et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010, 71(4):372-380.
26. Post R.M., Leverich G.L. Treatment of bipolar illness: a casebook for clinicians and patients 2008, 1-666. WW Norton and Company Inc, New York.
27. Post R.M., Altshuler L. Mood disorders: treatment of bipolar disorders. Comprehensive textbook of psychiatry 2009, 1743-1812. Lipincott Williams and William, New York. B.J. Sadock, V.A. Sadock, P. Ruiz (Eds.).
28. Kessing L.V., Sondergard L., Forman J.L., et al. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008, 65(11):1331-1335.
29. Forlenza O.V., Diniz B.S., Radanovic M., et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011, 198(5):351-356.
30. Greil W., Kleindienst N., Erazo N., et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998, 18(6):455-460.
31. Zhang Z.J., Kang W.H., Tan Q.R., et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007, 41(3-4):360-369.
32. Denicoff K.D., Smith-Jackson E.E., Disney E.R., et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997, 58(11):470-478.
33. Obrocea G.V., Dunn R.M., Frye M.A., et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002, 51(3):253-260.
34. Alda M., Passmore M.J., Garnham J., et al. Clinical presentation of bipolar disorders responsive to lithium or lamotrigine. Int J Neuropsychopharmacol 2002, 5(Suppl 1):S58.
35. Geddes J.R., Rendell J., Hinds C., et al. Comparative evaluation of quetiapine plus lamotigine versus quetiapine monotherapy in people with bipolar depression: a randomized trial (cequel) 2015, ISBD, Toronto.
36. Bowden C.L. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998, 19(3):194-199.
37. Van der Loos M., Mulder P., Hartong E., et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:223-231.
38. Calabrese J.R., Shelton M.D., Rapport D.J., et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005, 162(11):2152-2161.
39. Kemp D.E., Gao K., Fein E.B., et al. Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder. Bipolar Disord 2012, 14(7):780-789.
40. Ketter T.A. Handbook of diagnosis and treatment bipolar disorder 2010, Am Psych Pub, Inc, Washington, DC.
41. Geddes J.R., Rendell J.M., Goodwin G.M. BALANCE: a large simple trial of maintenance treatment for bipolar disorder. World Psychiatry 2002, 1(1):48-51.
42. Findling R.L., McNamara N.K., Youngstrom E.A., et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005, 44(5):409-417.
43. Berk M., Copolov D.L., Dean O., et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-double-blind randomized placebo-controlled trial. Biol Psychiatry 2008, 64(6):468-475.
44. Post R.M., Kalivas P. Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry 2013, 202(3):172-176.
45. Coppen A., Chaudhry S., Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986, 10(1):9-13.
46. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63(8):856-864.
47. Schoeyen H.K., Kessler U., Andreassen O.A., et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry 2015, 172(1):41-51.
48. Chaudhry H.R., Kahn R.M., Shabbir A., et al. Nimodipine in the treatment of bipolar disorder 2010, 232S. Society of Biological Psychiatry, New Orleans (LA).
49. Davanzo P.A., Krah N., Kleiner J., et al. Nimodipine treatment of an adolescent with ultradian cycling bipolar affective illness. J Child Adolesc Psychopharmacol 1999, 9(1):51-61.
50. Post R.M., Fleming J., Kapczinski F. Neurobiological correlates of illness progression in the recurrent affective disorders. J Psychiatr Res 2012, 46(5):561-573.
51. Wilens T.E., Biederman J., Millstein R.B., et al. Risk for substance use disorders in youths with child- and adolescent-onset bipolar disorder. J Am Acad Child Adolesc Psychiatry 1999, 38(6):680-685.
52. Lange K.J., McInnis M.G. Studies of anticipation in bipolar affective disorder. CNS Spectr 2002, 7(3):196-202.
53. Geller B., Tillman R., Bolhofner K., et al. Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up. Bipolar Disord 2010, 12(2):164-171.
54. Geller B., Luby J.L., Joshi P., et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 2012, 69(5):515-528.
55. Wagner K.D., Kowatch R.A., Emslie G.J., et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006, 163(7):1179-1186.
56. Findling R.L., Pathak S., Earley W.R., et al. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2014, 24(6):325-335.
57. Perlis R.H., Miyahara S., Marangell L.B., et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004, 55(9):875-881.
58. Post R.M., Altshuler L., Kupka R., et al. More pernicious course of bipolar disorder in the United States than in many European countries: implications for policy and treatment. J Affect Disord 2014, 160:27-33.
59. Post R.M., Altshuler L., Leverich G., et al. More stressors prior to and during the course of bipolar illness in patients from the United States compared with the Netherlands and Germany. Psychiatry Res 2013, 210(3):880-886.
60. Miklowitz D.J., Schneck C.D., Singh M.K., et al. Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy. J Am Acad Child Adolesc Psychiatry 2013, 52(2):121-131.
61. Axelson D., Goldstein B., Goldstein T., et al. Diagnostic precursors to bipolar disorder in offspring of parents with bipolar disorder: a longitudinal study. Am J Psychiatry 2015, 172(7):638-646.
62. Post R.M., Altshuler L.L., Leverich G.S., et al. Role of childhood adversity in the development of medical co-morbidities associated with bipolar disorder. J Affect Disord 2013, 147(1-3):288-294.
63. Kessing L.V., Hansen H.V., Hvenegaard A., et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry 2013, 202(3):212-219.